Latest Asx News

Discovery Alaska Limited has terminated its Vinasale Gold Project lease to conserve funds, while maintaining full ownership of the Chulitna Gold Project and exploring new opportunities to boost its portfolio.

Audalia Resources has completed critical drilling programs at its Medcalf vanadium-titanium-iron project, progressing resource upgrades and mine design while managing tight cash reserves and financing arrangements.

BWP Property Group and BWP Trust have launched a new Distribution Reinvestment Plan allowing stapled securityholders to reinvest cash distributions into additional securities, potentially at a discount and without transaction costs.

Environmental Clean Technologies has announced that CEO John Tranfield will resign effective 29 October 2025, with a transition period planned to support ongoing strategic initiatives.

ENRG Elements Limited has appointed new management and implemented significant cost reductions while renewing key uranium exploration permits in Niger. The company is also exiting lithium projects in Canada to focus on core assets and new opportunities.

Octava Minerals has secured a binding agreement to acquire the Federation Cu-Zn-Ag Project in Tasmania, reported promising bioleaching test results at its Byro REE-Li Project, and raised $1.5 million to fund exploration and working capital.

Battery Age Minerals Ltd has responded to an ASX price query, denying undisclosed information and attributing recent trading activity to a new research report and the launch of its maiden drilling program.

Taruga Minerals has exercised its option to acquire 100% of the Thowagee Project in Western Australia, reporting promising high-grade polymetallic rock chip and soil sampling results that expand exploration potential.

Australian Agricultural Projects Ltd has completed its 2025 harvest with a record 752,600 litres of high-quality extra virgin olive oil, setting the stage for improved cash flows and strategic restructuring.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Mount Burgess Mining advances metallurgical test work at its Nxuu deposit, navigates leadership changes, and pursues a significant legacy debt extinguishment as it refines its strategic focus.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.